Comparison between a linear versus a macrocyclic contrast agent for whole body MR angiography in a clinical routine setting by Seeger, Achim et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Journal of Cardiovascular Magnetic 
Resonance
Open Access Research
Comparison between a linear versus a macrocyclic contrast agent 
for whole body MR angiography in a clinical routine setting
Achim Seeger*1, Ulrich Kramer1, Michael Fenchel1, Florian Grimm1, 
Christiane Bretschneider1, Jörg Döring1, Bernhard Klumpp1, Gunnar Tepe1, 
Kilian Rittig2, Peter R Seidensticker3, Claus D Claussen1 and Stephan Miller1
Address: 1Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, 
Germany, 2Department of Internal Medicine IV, Eberhard-Karls-University Tuebingen, Otfried-Müller-Str. 10, 72076 Tuebingen, Germany and 
3Bayer Schering Pharma AG, 13342 Berlin, Germany
Email: Achim Seeger* - achim.seeger@gmx.de; Ulrich Kramer - ulrich.kramer@med.uni-tuebingen.de; 
Michael Fenchel - michael.fenchel@med.uni-tuebingen.de; Florian Grimm - florian.grimm@student.uni-tuebingen.de; 
Christiane Bretschneider - christiane.bretschneider@med.uni-tuebingen.de; Jörg Döring - joerg.doering@med.uni-tuebingen.de; 
Bernhard Klumpp - bernhard.klumpp@med.uni-tuebingen.de; Gunnar Tepe - gunnar.tepe@med.uni-tuebingen.de; 
Kilian Rittig - kilian.rittig@med.uni-tuebingen.de; Peter R Seidensticker - peter.seidensticker@bayerhealthcare.com; 
Claus D Claussen - claus.claussen@med.uni-tuebingen.de; Stephan Miller - stephan.miller@med.uni-tuebingen.de
* Corresponding author    
Abstract
Background: Previous experiences of whole body MR angiography are predominantly available in
linear 0.5 M gadolinium-containing contrast agents. The aim of this study was to compare image
quality on a four-point scale (range 1–4) and diagnostic accuracy of a 1.0 M macrocyclic contrast
agent (gadobutrol, n = 80 patients) with a 0.5 M linear contrast agent (gadopentetate dimeglumine,
n = 85 patients) on a 1.5 T whole body MR system. Digital subtraction angiography served as
standard of reference.
Results: All examinations yielded diagnostic image quality. There was no significant difference in
image quality (3.76 ± 0.3 versus 3.78 ± 0.3, p = n.s.) and diagnostic accuracy observed. Sensitivity
and specificity of the detection of hemodynamically relevant stenoses was 93%/95% in the
gadopentetate dimeglumine group and 94%/94% in the gadobutrol group, respectively.
Conclusion: The high diagnostic accuracy of gadobutrol in the clinical routine setting is of high
interest as medical authorities (e.g. the European Agency for the Evaluation of Medicinal Products)
recommend macrocyclic contrast agents especially to be used in patients with renal failure or
dialysis.
Background
Atherosclerosis is one of the leading challenges of health
care in developed countries. Due to the complex patho-
physiology and systemic nature of the cardiovascular sys-
tem [1] there is a need for accurate assessment of the
manifestations in order to offer best treatment, including
surgical and percutaneous catheter-based interventions as
well as pharmacological therapy. In this setting, Cardio-
vascular Magnetic Resonance (CMR) is increasingly used
[2-4].
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Current imaging strategies have been developed with lin-
ear 0.5 M contrast agents, for example gadopentetate
dimeglumine [2,4,5]. In the context of nephrogenic sys-
temic fibrosis (NSF) macrocyclic contrast agents are rec-
ommended to be used for contrast-enhanced MRI in
patients at risk [6-8]. The very high complex stability of
macrocyclic contrast agents decrease the risk to release
gadolinium ions in vivo. Gadobutrol (Gadovist™, Bayer
Schering Pharma, Germany) became the first macrocyclic
1.0 M contrast agent to receive approval from the Euro-
pean Union for contrast-enhanced MR angiography. Due
to its more compact bolus profile gadobutrol is well
suited for dynamic imaging (for example perfusion imag-
ing). As it is increasingly used in clinical routine for CMR
imaging, the diagnostic value of gadobutrol is of high
interest.
Using gadobutrol requires modifications with regard to
volume properties, circulation time and flow rates as
gadobutrol has a higher viscosity and is higher concen-
trated compared to gadopentetate dimeglumine. Accord-
ing to our knowledge, no comparison of the diagnostic
performance of gadobutrol to the standard gadopentetate
dimeglumine in whole body MR-Angiographie (WBMRA)
in a large patient group using the identical sequence pro-
tocol has been reported. Aim of this study was to compare
image quality and diagnostic accuracy in WBMRA in a
clinical routine setting in 165 patients (gadopentetate
dimeglumine n = 85, gadobutrol n = 80). Conventional X-
ray angiography served as standard of reference and was




In this retrospective analysis we included 165 patients
with clinical evidence of peripheral artery disease (PAD,
Fontaine stage IIb-IV) who underwent DSA and WBMRA
within 14 days from January 2004 to June 2007. The
patients were examined either using the 0.5 M gadopen-
tetate dimeglumine (Magnevist™, Bayer Schering Pharma,
Germany) or the 1.0 M gadobutrol (Gadovist™, Bayer
Schering Pharma, Germany) which was mainly used after
the knowledge that NSF might be associated with the
release of gadolinium ions in vivo.
The mean age in the gadopentetate dimeglumine group (n
= 85, 66 male, 19 female) was 66 ± 10.1 years and in the
gadobutrol group (n = 80, 58 male, 22 female) 67 ± 11.9
years. A glomerular filtration rate < 30 mg/dl according to
the Cockcroft-Gault formula was present in 5 patients
(gadopentetate dimeglumine group n = 2, gadobutrol
group n = 3).
MR Imaging protocol
All examinations were performed on a 1.5 T whole body
MR-scanner (Magnetom Avanto, Siemens Medical Solu-
tions, Erlangen, Germany). For signal reception, surface
coils were used for all body regions. Four overlapping
fields of view of 500 mm were used for covering the arte-
rial vascular system (see table 1 for imaging parameters
and Fig. 1). Scout images were obtained from all stations.
Unenhanced and enhanced images were acquired from
the abdominal region and the upper and lower leg area by
using 3D FLASH sequences, the time to move the table
between the stations was about 2–3 seconds. 15 minutes
after the first contrast medium application unenhanced
and enhanced images of the neck and head were meas-
ured.
Acquisition and Analysis Figure 1
Acquisition and Analysis. the four overlapping fields of 
view (head and neck; thorax and abdomen; upper leg; lower 
leg) that were used for acquisition. On the right side, the 31 
segments for image analysis are labelled. The figure shows a 
3D reconstruction of the vascular tree of an 50 year old man 
with stent in the common iliac arteries. Contrast agent for 
WBMRA in this patient was gadobutrol.Journal of Cardiovascular Magnetic Resonance 2008, 10:63 http://www.jcmr-online.com/content/10/1/63
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Contrast media and injection
In total 0.25 mmol/kg body weight (bw) contrast media
was injected. The scan delay was determined with a sagit-
tal test bolus section angled to the course of the aorta. An
automated injector (Spectris, Medrad) was used in all
examinations. Gadobutrol was administered at a flow rate
of 1.2 ml/s (depending on the patients weight 10–13 ml
for the abdominal region and the legs resulting in a typical
bolus duration of 8–11 seconds and 5–7 ml for the head
and neck), Gadopentetate dimeglumine was injected with
biphasic flow for the abdomen and legs (0.15 mmol/kg
bw @ 2 ml/s followed by 0.03 mmol/kg bw @ 1 ml/s
resulting in a typical bolus duration of 10–16 seconds).
All contrast injections were followed immediately by a
saline flush (25 ml @ 1.0 ml/s).
A timing bolus was used (gadopentetate dimeglumine 2
ml or gadobutrol 1 ml) followed by 25 ml saline flush and
image delay was calculated according to the following for-
mula:
Tcir - Tk + 4 sec (where Tcir is the circulation time and Tk is
the time to the k-space center line).
Conventional Digital Subtraction Angiography (DSA)
DSA of the area of suspected pathology based upon the
symptoms (either comprising the abdominal aorta, the
renal and pelvic arteries and the arteries of the lower
extremities or in some cases only the symptomatic lower
extremity) was performed with a standard angiographic
unit (Axiom Artis TA; Siemens Medical Systems) using a 4
French straight catheter transfemorally and 20 ml of con-
trast agent (Ultravist 370™, Bayer Schering Pharma, Ger-
many) was administered at each station. As required,
examinations were supplemented with acquisition of one
or more oblique views of the arteries.
Image analysis
Baseline images were subtracted from the contrast-
enhanced images for each station and maximum intensity
projection reconstruction images were performed. All
WBMRA images were assessed by two readers consensus
reading. The maximum intensity projection reconstruc-
tions and the contrast enhanced source images were used
for image analysis on a segment-by-segment basis. DSA
images were evaluated by an experienced radiologist who
had 8 years of experience in diagnostic and interventional
angiographic procedures.
For image evaluation the vascular system was classified
into a total of 31 arterial segments (see Fig.1). The readers
were blinded to clinical symptoms, contrast agent and
DSA. A four-level system rate for image quality of each
arterial segment was used (1 = non-diagnostic images, 2 =
poor image quality, significant blurring/artefacts, diagno-
sis suspected but not established, 3 = good quality with
definite diagnosis, minimal blurring/artefacts, 4 = sharply
defined borders, excellent quality image information).
The images were evaluated for presence of venous super-
imposition that hampered image analysis and required a
multiplanar reconstruction of the contrast-enhanced data
sets.
Each vascular segment was assessed for the presence of
hemodynamically relevant stenosis (which was defined as
luminal narrowing of 70–99%) or occlusion.
MRA and DSA were compared in all segments for which
data from both modalities were available.
Statistical analysis
Continuous data are presented as mean ± standard devia-
tion. Quantitative variables were tested for statistical sig-
nificance by using a Student t-test. Statistical significance
was defined by p < 0.05. All p-value were two tailed.
The results of WBMRA and DSA were compared in every
available segment. Sensitivity, specificity, positive and
negative predictive value and accuracy for the detection of
hemodynamically relevant stenosis as well as Cohen κ
value agreement were calculated.
Results
Qualitative analysis
All examinations (gadopentetate dimeglumine n = 85,
gadobutrol n = 80) yielded diagnostic image quality. A
total of 5115 vascular segments (31 segments per patient
in 165 patients) were evaluated for the presence of vascu-
Table 1: Imaging parameters.
TR (ms) TE (ms) FA (°) FOV (mm2) Matrix Slice (mm) GRAPPA TA (sec) Bandwidth (Hz/Px)
Head and Neck 2.85 1.68 25 344 × 500 264 × 512 1.6 x2 17 650
Abdomen 3.11 1.14 25 375 × 500 230 × 512 1.5 x2 13 420
Upper Leg 3.46 1.21 25 375 × 500 230 × 512 1.5 x2 12 360
Lower Leg 3.46 1.21 25 375 × 500 230 × 512 1.3 x2 13 360
Table 1 shows the imaging parameters of WBMRA of the 4 overlapping segments that are shown in Fig.1. Generalized autocalibrating partially 
parallel acquisition (GRAPPA) in phase encoding direction was used. Scan duration times for a single station were 12 – 17 seconds (time of 
acquisition, TA).Journal of Cardiovascular Magnetic Resonance 2008, 10:63 http://www.jcmr-online.com/content/10/1/63
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lar disease and image quality. The mean rating was 3.77 ±
0.3, there was no significant difference between the image
quality rating of gadopentetate dimeglumine (3.76 ± 0.3)
compared to gadobutrol (3.78 ± 0.3; p = n.s.).
Subject motion was the most common reason for reduced
image quality in 12 patients (gadopentetate dimeglumine
n = 5, gadobutrol n = 7). Venous superimposition in the
lower leg that hampered the diagnostic assessment was
evident in 10 patients (gadopentetate dimeglumine n = 6,
gadobutrol n = 4).
DSA findings
DSA of the symptomatic region was available in 2757 seg-
ments (1456 segments in the gadopentetate dimeglumine
group and 1301 segments in the gadobutrol patients, see
Fig.2).
In 2153 segments (1164 gadopentetate dimeglumine,
989 gadobutrol) no stenosis was seen, 249 segments (106
gadopentetate dimeglumine and 143 gadobutrol) showed
a stenosis > 70% and 355 segments showed a vascular
occlusion (186 gadopentetate dimeglumine and 169
gadobutrol).
Study Population and Results Figure 2
Study Population and Results. the flow diagram of the 
study population and the results of the correlation between 
DSA and WBMRA.
Example gadopentetate dimeglumine Figure 3
Example gadopentetate dimeglumine. 41 year old man 
with peripheral arterial occlusive disease stage Fontaine IIb 
(pain in both legs) and Y-prothesis. The left side shows the 
WBMRA (maximum intensity projection), on the right side 
the DSA. Both modalities show the occlusion of the superfi-
cial femoral arteries (arrows) and a stenosis of the right renal 
artery (arrows in the expanded images).Journal of Cardiovascular Magnetic Resonance 2008, 10:63 http://www.jcmr-online.com/content/10/1/63
Page 5 of 9
(page number not for citation purposes)
Correlation WBMRA to DSA
Fig.3 and Fig.4 show examples of the correlation between
a maximum intensity projection WBMRA and DSA in
both contrast agents.
In the gadopentetate dimeglumine group, 1369 of 1456
segments were correctly diagnosed (1100 without steno-
sis, 84 relevant stenoses and 175 vascular occlusions).
WBMRA resulted in 16 false-negative vessel segments and
47 false-positive segments, 7 segments were overesti-
mated and 6 segments underestimated.
In the gadobutrol group, 1212 of 1301 segments were cor-
rectly diagnosed (932 without stenosis, 122 relevant sten-
oses and 158 vascular occlusions). WBMRA resulted in 15
false-negative segments and 46 false-positive segments, 6
vessel segments were overestimated and 6 segments
underestimated. While overall sensitivity/specificity for
the detection of stenoses or occlusions in the gadopen-
tetate dimeglumine group was 93%/95% it was 94%/94%
using gadobutrol, respectively. Diagnostic accuracy was
95% for both contrast agents. Overall Kappa value agree-
ment between WBMRA and DSA was 0.83 for gadopen-
tetate dimeglumine as well as gadobutrol (see Fig.2).
Table 2 shows sensitivities, specificities, negative and pos-
itive predictive values and diagnostic accuracies in all seg-
ments for both study groups. In all vascular segments
WBMRA showed good correlation to DSA, even in the
lower leg regions there was high diagnostic accuracy in
depiction of hemodynamically relevant stenoses. There
were no statistically significant differences in the diagnos-
tic performance between the study groups.
Discussion
Atherosclerosis is a systemic disease that may involve the
entire arterial system in man. Knowledge of coexisting
lesions enables the appropriate treatment in a systemic
context. In this setting WBMRA is increasingly used for
vascular staging with high diagnostic accuracy compared
to DSA as reference standard and its clinical impact on
patient management has been shown in previous studies
[3,9].
Because of the doubled gadolinium concentration of
gadobutrol injection protocols like flow rate and injection
volume have to be adapted to adjust the vascular enhance-
ment to the acquisition window. While gadobutrol has
been used in earlier studies with a rolling system (Angio-
SURF™, System for Unlimited Rolling Fields-of-View, MR-
Innovation, Essen, Germany) [9,10] the published data
using whole body scanners (TIM™, Total Imaging Matrix,
Siemens, Germany) have been performed using 0.5 M
extracellular gadolinium chelates like gadopentetate
dimeglumine [5,11,12]. In this study the injection proto-
col of both gadopentetate dimeglumine and gadobutrol
was optimised according to the experience of our institu-
tion. The mean gadobutrol injection rate in a multicenter
study [13] was in correspondence to our protocol 1.2 ml/
s and a high diagnostic accuracy for MRA of the body
using versus DSA has been proved. The reported agree-
ment rate of Schaefer et al. was 96.6% in the clinical eval-
uation and 86.6–90.2% in the independent blinded
reader evaluation, but no comparison to a standard 0.5 M
contrast agent has been performed in this study.
The published data on the potential benefits of gado-
butrol to 0.5 M Gd-chelates are controversial. Goyen et al.
reported an improved delineation of blood vessels in
WBMRA [9] in a small patient group (3 volunteers, 10
patients) as well as an improved delineation of small ves-
sels in the pelvic vascular territory [14]. Benefits in first-
pass T2*-weighted cerebral perfusion have also been
reported [15] while other studies showed no advantage of
Gadobutrol for CE-MRA of the lung, abdomen as well as
first-pass cardiac and pulmonary perfusion [16-18].
The purpose of our study was to compare the diagnostic
performance of the 0.5 M gadopentetate dimeglumine
and the 1.0 M gadobutrol in whole body MRA in a large
patient group suffering from PAD using identical
sequence parameters.
We found good to excellent image quality in both, the 0.5
M and the 1.0 M contrast agent. No significant difference
in image quality between the two study groups was
detected. Limitations in image quality were caused by sub-
ject motion of venous superimposition without signifi-
cant differences in the two groups. Venous contamination
could potentially be reduced by the use of thigh compres-
sion [19], nevertheless due to the rare appearance it is not
routinely performed in our institution. An alternative
approach to increase the image quality is the application
of blood pool contrast agents like gadofosveset (Vaso-
vist™, Bayer Schering Pharma, Germany). However the
diagnostic benefit of blood pool contrast agents in
WBMRA is still under investigation.
In comparison to conventional X-ray angiography, severe
vascular occlusive disease was correctly diagnosed in an
overall sensitivity/specificity of 93/95% (gadopentetate
dimeglumine) and 94/94% (gadobutrol), respectively.
Diagnostic accuracy (95%) and Kappa value agreement
(0.83) was identically for both study groups. The values
are close to those reported in the literature. Overestima-
tion of stenoses was more frequently found than underes-
timation and is a known limitation of MRA [20].
Although i.a. DSA is accepted as the reference standard,
discrepancies between WBMRA and DSA can be due to
errors in either modality. The three-dimensional nature ofJournal of Cardiovascular Magnetic Resonance 2008, 10:63 http://www.jcmr-online.com/content/10/1/63
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Example gadobutrol Figure 4
Example gadobutrol. 79 year old man with peripheral arterial occlusive disease stage Fontaine IIb (pain in the right leg) and 
stent in the right renal artery. The left side shows the WBMRA (maximum intensity projection), on the right side the DSA. 
Both modalities show the occlusion of the right superficial femoral artery (arrows) and the accurate correlation, for example 
the lesions in the right anterior tibial artery (arrows in the expanded images).Journal of Cardiovascular Magnetic Resonance 2008, 10:63 http://www.jcmr-online.com/content/10/1/63
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WBMRA images potentially allows superior depiction of
eccentric stenoses compared with the two-dimensional
DSA.
As the needed dose for WBMRA is higher than for a single
station MRA, a well tolerated contrast agent that allows
high image quality should be chosen. Gadobutrol is
Table 2: Result correlation WBMRA-DSA
Gadopentetate dimeglumine Gadobutrol
Sensitivity Specificity NPV PPV Accuracy Sensitivity Specificity NPV PPV Accuracy
Suprarenal aorta - 100 100 - 100 100 100 100 100 100
Infrarenal aorta 100 100 100 100 100 100 100 100 100 100
Right renal artery 100 98 100 75 98 100 97 100 83 98
Left renal artery 100 100 100 100 100 100 100 100 100 100
Right common iliac artery 86 96 98 75 95 100 97 100 92 98
Left common iliac artery 100 98 100 86 98 94 100 97 100 98
Right external iliac artery 100 98 100 86 98 100 93 100 63 96
Left external iliac artery 100 98 100 89 98 100 100 100 100 100
Right common femoral artery 71 100 96 100 97 80 98 98 80 96
Left common femoral artery 80 98 98 80 97 88 96 98 78 95
Right SFA (proximal) 100 91 100 79 93 90 98 95 95 97
Left SFA (proximal) 100 94 100 88 97 96 97 97 96 97
Right SFA (distal) 87 95 92 91 93 97 93 97 94 95
Left SFA (distal) 89 95 93 92 94 100 94 100 94 97
Right popliteal artery 100 96 100 75 97 70 96 94 78 91
Left popliteal artery 93 98 98 93 97 83 98 96 91 97
Right tibioperoneal trunk 86 96 98 75 95 100 96 100 75 96
Left tibioperoneal trunk 91 93 98 71 92 100 98 100 88 98
Right ant. tibial artery 94 94 94 94 94 94 82 97 68 87
Left ant. tibial artery 95 87 98 76 89 94 88 97 75 90
Right peroneal artery 93 88 97 74 93 83 84 95 59 88
Left peroneal artery 94 83 98 68 89 81 86 92 68 88
Right posterior tibial artery 95 95 97 91 95 96 84 96 82 93
Left posterior tibial artery 93 89 94 87 91 96 80 97 76 88
Table 2 shows the result of the WBMRA of both groups (gadopentetate dimeglumine and gadobutrol) in correlation to DSA as standard of 
reference in all available arterial segments.Journal of Cardiovascular Magnetic Resonance 2008, 10:63 http://www.jcmr-online.com/content/10/1/63
Page 8 of 9
(page number not for citation purposes)
known to be well tolerated [21,22] and in the context of
NSF it is less likely prone to release Gadolinium ions in
vivo. Due to the high co-morbidity of peripheral arterial
disease (PAD) and renal failure, contrast-enhanced MR
angiography (CE-MRA) is frequently indicated in this
patient group [23] and gadobutrol might be increasingly
used in risk patients.
New developments in sequence technique, parallel acqui-
sition and fast-gradient technology allow rapid scan times
to avoid venous enhancement and to achieve higher spa-
tial resolution. In this setting, gadobutrol has the poten-
tial to enable a sharper bolus peak and therefore higher
intravascular gadolinium concentration and may com-
pensate the diminished SNR due to smaller voxel size.
A limitation is the fact that the comparison of the two
study groups was based on qualitative parameters and the
measurement of quantitative date like signal-to-noise
ratio and contrast-to-noise ratio would be desirable. How-
ever applying parallel imaging techniques comes along
with the problem that quantitative analysis require a com-
plex correction [24] and is not relevant for the clinical rou-
tine use.
Conclusion
We found a very good agreement between DSA and
WBMRA in both contrast agents. WBMRA using the 1.0 M
gadobutrol allows injection of less contrast agent volume
and achieves comparable diagnostic accuracies to
reported results of gadopentetate dimeglumine.
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